Form 4: BioCryst Executive Boosts Stake with Option Exercises

BioCryst Pharmaceuticals' President and CCO, Charles K. Gayer, increased his direct beneficial ownership of common stock through the exercise of employee stock options.

Summary

• Charles K. Gayer, President and Chief Commercial Officer (CCO) of BioCryst Pharmaceuticals Inc. (BCRX), reported transactions involving the company's common stock.
• On December 19, 2025, 11,477 shares of common stock were withheld by the Issuer at a price of $7.41 per share to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units.
• On December 22, 2025, Mr. Gayer exercised employee stock options to acquire a total of 74,233 shares of common stock.
• These exercises included 14,142 shares at an exercise price of $3.22, 10,091 shares at an exercise price of $5.04, and 50,000 shares at an exercise price of $5.51.
• Following these transactions, Mr. Gayer's direct beneficial ownership of BioCryst Pharmaceuticals common stock increased to 952,583 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the transactions are routine, the net increase in direct beneficial ownership by a key executive can be interpreted as a sign of confidence in the company's future, which is generally a positive signal for investors.

Positives

• The exercise of employee stock options by a key executive, Charles K. Gayer, indicates continued confidence in the company's future prospects.
• The net increase in direct beneficial ownership by the President and CCO aligns management's interests more closely with those of shareholders.

Negatives

• 11,477 shares were withheld for tax obligations, which is a standard procedure for vesting restricted stock units and not a direct sale by the executive.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, particularly option exercises that result in increased beneficial ownership, are generally viewed by the market as a positive signal, suggesting that management believes the company's stock is undervalued or has strong future prospects. This is a routine transaction for executives with vested stock options.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive indicator of management's alignment with shareholder interests and confidence in the company's long-term value.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (option exercises and tax withholdings) by a key executive. While the net increase in beneficial ownership is a positive signal of management confidence, it does not provide new fundamental information about BioCryst Pharmaceuticals' operational performance, financial health, or strategic direction that would warrant a change in investment recommendation based solely on this filing. Investors should consider this information in the broader context of the company's financial reports and market conditions.

Keywords

BIOCRYST PHARMACEUTICALS, BCRX, Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Executive Compensation